Issue 6/2005
Content (12 Articles)
Elimination of the differential chemoresistance between the murine B-cell lymphoma LY-ar and LY-as cell lines after arsenic (As2O3) exposure via the overexpression of gsto1 (p28)
U. Giri, N. H. A. Terry, S. V. Kala, M. W. Lieberman, M. D. Story
A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors
Grace K. Dy, Ajit Suri, Joel M. Reid, Jeff A. Sloan, Henry C. Pitot, Steven R. Alberts, Richard M. Goldberg, Pamela J. Atherton, Lorelei J. Hanson, Patrick A. Burch, Joseph Rubin, Charles Erlichman, Alex A. Adjei
Molecular mechanisms of ginsenoside Rh2-mediated G1 growth arrest and apoptosis in human lung adenocarcinoma A549 cells
Chi-Chih Cheng, Shu-Mei Yang, Chi-Ying Huang, Jung-Chou Chen, Wei-Mao Chang, Shih-Lan Hsu
5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens
Omar N. Al Safarjalani, Xiao-Jian Zhou, Reem H. Rais, Junxing Shi, Raymond F. Schinazi, Fardos N. M. Naguib, Mahmoud H. el Kouni
Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences
Maki Ando, Hideo Saka, Yuichi Ando, Hironobu Minami, Takafumi Kuzuya, Masashi Yamamoto, Atsushi Watanabe, Shuzo Sakai, Kaoru Shimokata, Yoshinori Hasegawa
A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer
Henry Q. Xiong, William Plunkett, Robert Wolff, Min Du, Renato Lenzi, James L. Abbruzzese
Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies
Debora G. Rodrigues, Durvanei A. Maria, Denise C. Fernandes, Claudete J. Valduga, Ricardo D. Couto, Olga C. M. Ibañez, Raul C. Maranhão
Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175
R. L. Hayward, Q. C. Schornagel, R. Tente, J. S. Macpherson, R. E. Aird, S. Guichard, A. Habtemariam, P. Sadler, D. I. Jodrell
Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells
Osamu Kishida, Yoshiji Miyazaki, Yoko Murayama, Miyuki Ogasa, Tamana Miyazaki, Takahiro Yamamoto, Kenji Watabe, Shusaku Tsutsui, Tatsuya Kiyohara, Iichiro Shimomura, Yasuhisa Shinomura
In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines
Risa Tanaka, Hiroshi Ariyama, Baoli Qin, Yasushi Takii, Eishi Baba, Kenji Mitsugi, Mine Harada, Shuji Nakano
Additive apoptotic effect of STI571 with the cytoprotective agent amifostine in K-562 cell line
Luciano Vellón, Marcela González-Cid, Marcelo de Campos Nebel, Irene Larripa
Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients
Peter Nygren, Kenneth Hande, Kevin J. Petty, Margaret Fedgchin, Kristien van Dyck, Anup Majumdar, Debbie Panebianco, Marina de Smet, Tuli Ahmed, M. Gail Murphy, Keith M. Gottesdiener, Veronique Cocquyt, Simon van Belle